BCAB - CIK 0001826892
The table below shows BioAtla, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $300.00K | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $43.57M | $63.09M | $103.73M | $79.35M | $58.27M | $19.93M |
| SG&A | $17.73M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $21.85M |
| $25.96M |
| $28.79M |
| $38.42M |
| $10.60M |
| Operating income | -$59.30M | -$73.94M | -$129.69M | -$108.14M | -$96.44M | -$30.10M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$59.61M | -$69.78M | -$123.46M | -$106.48M | -$95.40M | -$35.85M |
| EPS (diluted) | -$1.01 | -$1.44 | -$2.58 | -$2.74 | -$2.76 | - |